CESTAT upholds order in company's favour, confirms entitlement to refund of CENVAT credit of Rs. 2751 Lakhs
CESTAT Mumbai upheld the Order-in-Appeal dated 27.04.2018 passed in favour of the Company and confirmed its entitlement to refund of accumulated CENVAT credit of Rs. 2751 Lakhs, along with consequential interest where applicable.
- Refund Amount Confirmed
- Rs. 2751 Lakhs
- Order-in-Appeal Date
- 27.04.2018
- Tribunal
- CESTAT Mumbai
- Outcome
- The Revenue's appeal has been dismissed
- Refund Subject Matter
- refund of accumulated CENVAT credit
Litigation decided in the Company's favour
The Company has informed the stock exchanges about a development in a litigation it had disclosed earlier. The matter was before the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai, and relates to the case listed at Sr. No. 3 of the Company's earlier intimation dated August 14, 2023.
What the Tribunal decided
- The Tribunal has upheld the Order-in-Appeal dated 27.04.2018 that was passed in favour of the Company.
- It has confirmed the Company's entitlement to refund of accumulated CENVAT credit, along with consequential interest, where applicable, for an amount of Rs. 2751 Lakhs.
- The litigation stands decided in favour of the Company and the Revenue's appeal has been dismissed.
How to read this
This is an update on a legal dispute, not on the Company's business operations. The order confirms an entitlement to a refund of accumulated CENVAT credit of Rs. 2751 Lakhs, along with consequential interest where applicable. The phrase "where applicable" is the update's own wording for the interest element.
What the disclosure covers
- The update is given as a change in status of a proceeding the Company had already disclosed to the exchanges.
- The proceeding was pending before the Tribunal, and the Revenue's appeal in it has been dismissed.
For a retail investor, the key point is that a pending indirect tax dispute has been decided in the Company's favour, with the Tribunal confirming the entitlement to refund of Rs. 2751 Lakhs along with consequential interest, where applicable.
Also from Sun Pharma Advanced Research Company
Sun Pharma signed a global exclusive licensing deal with LIB Therapeutics to commercialize a cholesterol-lowering drug outside the US and China, sparking bullish brokerage views
29 Sep 2026
More numbers
- Accumulated CENVAT credit refund confirmed by the TribunalRs. 2751 Lakhs
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.